Traders purchased shares of Medivation Inc. (NASDAQ:MDVN) on weakness during trading on Wednesday. $160.51 million flowed into the stock on the tick-up and $139.20 million flowed out of the stock on the tick-down, for a money net flow of $21.31 million into the stock. Of all equities tracked, Medivation had the 4th highest net in-flow for the day. Medivation traded down ($0.04) for the day and closed at $80.23

A number of analysts have recently issued reports on MDVN shares. Wedbush restated a “buy” rating on shares of Medivation in a research report on Saturday, April 30th. Leerink Swann set a $64.00 price objective on Medivation and gave the company a “hold” rating in a research report on Wednesday, August 10th. Barclays PLC restated a “buy” rating on shares of Medivation in a research report on Sunday, May 8th. TheStreet lowered Medivation from a “buy” rating to a “hold” rating in a research note on Wednesday, August 10th. Finally, Canaccord Genuity reaffirmed a “buy” rating and issued a $82.00 price target (up previously from $70.00) on shares of Medivation in a research note on Tuesday. One equities research analyst has rated the stock with a sell rating, eighteen have given a hold rating and five have assigned a buy rating to the company. Medivation has a consensus rating of “Hold” and a consensus price target of $76.96.

The stock has a 50 day moving average of $64.87 and a 200 day moving average of $53.32. The firm’s market capitalization is $13.31 billion.

Medivation (NASDAQ:MDVN) last announced its earnings results on Tuesday, August 9th. The biopharmaceutical company reported $0.29 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.27 by $0.02. The company had revenue of $206 million for the quarter, compared to analyst estimates of $214.52 million. The firm’s quarterly revenue was up 17.4% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.58 earnings per share. Analysts predict that Medivation Inc. will post $1.27 EPS for the current fiscal year.

In other Medivation news, SVP Andrew Kenneth William Powell sold 2,578 shares of Medivation stock in a transaction dated Monday, June 6th. The stock was sold at an average price of $60.42, for a total transaction of $155,762.76. Following the transaction, the senior vice president now directly owns 28,517 shares of the company’s stock, valued at approximately $1,722,997.14. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Other hedge funds and institutional investors recently made changes to their positions in the company. Bank of Montreal Can increased its position in shares of Medivation by 8.0% in the fourth quarter. Bank of Montreal Can now owns 38,138 shares of the biopharmaceutical company’s stock valued at $1,844,000 after buying an additional 2,836 shares during the last quarter. Advisors Asset Management Inc. raised its position in Medivation by 16.6% in the fourth quarter. Advisors Asset Management Inc. now owns 25,952 shares of the biopharmaceutical company’s stock valued at $1,255,000 after buying an additional 3,688 shares during the period. I.G. Investment Management LTD. raised its position in Medivation by 10.2% in the fourth quarter. I.G. Investment Management LTD. now owns 56,420 shares of the biopharmaceutical company’s stock valued at $2,727,000 after buying an additional 5,200 shares during the period. KBC Group NV raised its position in Medivation by 98.7% in the fourth quarter. KBC Group NV now owns 32,177 shares of the biopharmaceutical company’s stock valued at $1,556,000 after buying an additional 15,984 shares during the period. Finally, Schwab Charles Investment Management Inc. raised its position in Medivation by 12.5% in the fourth quarter. Schwab Charles Investment Management Inc. now owns 349,297 shares of the biopharmaceutical company’s stock valued at $16,886,000 after buying an additional 38,893 shares during the period.

Medivation, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to treat serious diseases for which there are limited treatment options. The Company, in collaboration with Astellas Pharma, Inc (Astellas), has one commercial product, XTANDI (enzalutamide) capsules (XTANDI).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.